is a common consequence of traumatic brain injury (TBI), and is a source of substantial distress and disability for persons with TBI and their families. This article offers a practical approach to the evaluation and treatment of this condition. Diagnostic and etiologic considerations relevant to this issue are reviewed first. Next, somatic therapies for posttraumatic depression, including antidepressant medications and electroconvulsive therapy, are discussed. Use of these therapies is also considered in the context of the common medical and neurological comorbidities among persons with TBI. Finally, psychosocial interventions relevant to the care of persons with posttraumatic depression are presented.
D
EPRESSION is the most common mood disorder after traumatic brain injury (TBI), with estimates of posttraumatic depression ranging between 10% and 77%. 1, 2 The variability in the rates of depression after TBI most likely reflects between-study differences in diagnostic criteria (whether just presence of depressive symptoms versus different diagnostic criteria for depression), severity of TBI, use of incidence or prevalence rates, the time after TBI when diagnosis is made, different patient populations (acute rehabilitation versus random selection versus responders to ad-vertisements), and whether individuals with a history of depression prior to their injury are included. Nonetheless, the rates of posttraumatic depression are high in the first year following injury, 3 and the risk for developing depression appears to remain elevated even decades after TBI. 4 Depression after TBI also increases the risk for developing other neuropsychiatric problems, including increased suicidality, [5] [6] [7] cognitive dysfunction, [8] [9] [10] and aggressive behavior, 11, 12 that may contribute to morbidity and functional disability after TBI. [13] [14] [15] Posttraumatic depression is associated with relatively poor psychosocial outcome, increased psychological distress, and both a greater number and perceived severity of postconcussive symptoms. 13, 16 In addition, posttraumatic depression interferes with physical and cognitive rehabilitation. 15 In light of these findings, the importance of recognizing, diagnosing, and treating posttraumatic depression cannot be overstated.
This article provides first a brief review of diagnostic and etiologic considerations relevant to this issue. Pharmacologic treatments and electroconvulsive therapy are then presented. At the outset of this presentation, readers should be aware that there are no multicenter, randomized, double-blind, placebocontrolled trials of any treatment for posttraumatic depression. Instead, the literature in this area consists of case reports, case series, open-label studies, and a few single-site singleor double-blind controlled studies. While informative, these studies render any recommendations made-herein or elsewhereregarding the treatment of posttraumatic depression preliminary, at best. With this in mind, the presentation of treatments for posttraumatic depression herein provides information regarding the design of and findings from studies published in the peer-reviewed literature to date. On the basis of both these studies and our clinical experience using these agents in this population, suggestions regarding the treatment of persons with depression are offered. Special considerations regarding the use of these interventions in this population are presented given the medical and neurological comorbidities common among persons with TBI. Finally, psychosocial issues relevant to the care of persons with posttraumatic depression are presented.
DIAGNOSTIC CONSIDERATIONS
The first step in effectively treating depression after TBI is making an accurate diagnosis. Many of the physical symptoms produced by TBI overlap with, and may contribute to, those associated with depression, including chronic pain, headaches, vestibular dysfunction, and sleep disruption. 17 Despite this overlap, the use of standard diagnostic criteria for depression appears to be appropriate in this context. For example, Jorge et al 18 validated the Diagnostic and Statistical Manual-III-Revised (DSM-III-R) criteria for diagnosis of major depressive disorder after TBI, and demonstrated 100% sensitivity and 94% specificity at initial evaluation, and 80% sensitivity and 100% specificity at evaluation 1 year postinjury. The use of structured or semistructured psychiatric interviews like the Present State Exam, Structured Clinical Interview for DSM-IV, or the Schedules for Clinical Assessment in Neuropsychiatry may also be useful in both establishing a diagnosis of posttraumatic depression and assessing the severity of that condition. 19 Other measures that may be useful in these regards include the Beck Depression Inventory (BDI), 20 the Hamilton Depression Scale (HAM-D), the Neurobehavioral Functioning Inventory Depression Scale, 21 and the Center for Epidemiologic Scales for Depression. 19 When possible, use of scales or measures rated by a professional provider or a caregiver (ie, HAM-D) may either augment or sometimes offer advantages over self-report measures (ie, BDI) in light of the fact that persons with TBI may be limited with respect to insight into their symptoms and related disabilities. 22−24 For example, Sliwinski et al 25 demonstrated the BDI to have only 36% sensitivity (with specificity set at 80%) in the diagnosis of depression after TBI, which stands in contrast to the rather more robust finding reported by Jorge et al 18 when applying DSM-III-R criteria as assessed by a clinician. Similarly, Turner-Stokes et al 26 used an integrated care pathway (ICP) in an acute rehabilitation setting for the management of depression after TBI. The ICP included screening for depression using clinical assessment and DSM-IV criteria, and the Beck Depression Inventory II (evaluator administered) at initial evaluation, before treatment, and then at 6-8 weeks after treatment with sertraline. They reported the ICP as practical to use in that it provided both objectively and subjectively obtained data on both depression assessment and response to treatment in the acute rehabilitation setting. In addition to supporting the use of such measures in the service of diagnosis, their findings also lend support to the suggestion that use of such measures facilitates a more accurate assessment of response to treatments offered to persons with posttraumatic depression.
Persons with a history of TBI are at increased risk for many psychiatric disorders when compared to the general population, including major depression, dysthymia, panic disorder, obsessive compulsive disorder, phobic disorder, and drug abuse and dependence. 10 In light of the variety of neuropsychiatric problems experienced by persons with TBI, it is important to consider carefully each of these as alternate or comorbid diagnoses in this population. Among these conditions, apathy and anxiety are particularly important diagnostic considerations. Apathy refers to a decrease in goal-directed cognition, emotion, and behavior whereas depression denotes a state of excessive and persistent sadness. Although persons with depression may also experience apathy, some will present with apathy without depression. The treatment of these syndromes differs considerably, with serotonergic antidepressants treating depression (with or without apathy) following TBI quite effectively (as discussed below) but often not treating, or even occasionally worsening, apathy alone. Anxiety is frequently comorbid with depression following TBI, with rates as high as 77%. 12 Accordingly, identification of anxiety among persons with depression following TBI is imperative, and may influence the selection of treatments that have a high likelihood of effectively reducing both depressive and anxious symptoms.
When attempting to make these diagnostic distinctions, identifying the presence of fatigue, poor concentration, distractibility, anger or irritability, rumination, and frustration may be useful in that these symptoms favor a diagnosis of posttraumatic depression. 27, 28 Similarly, hopelessness, worthlessness, and difficulty enjoying activities (rather than simply initiating activities) are 3 symptoms that are particularly suggestive of the presence of posttraumatic depression. 28 Although these symptoms are not uniformly observed among persons with posttraumatic depression, their presence strongly suggests the need for treatment of this condition.
ETIOLOGY OF POSTTRAUMATIC DEPRESSION
Both neurobiological (ie, injury-related) and psychosocial factors contribute to the development and persistence of depression after TBI, and it is likely that the relative contributions of these factors varies considerably from person to person. 29 The relationship between injury severity and posttraumatic depression is controversial and potentially counterintuitive, with higher rates of depression occurring among persons with mild TBI than among those with severe TBI. [30] [31] [32] While it is tempting to speculate on the nature of this inverse relationship between injury severity and posttraumatic depression, suffice it to say for our purpose here that depression may develop following TBI of any severity and should be treated regardless of the mechanism by which that depression is believed to relate to the initial injury.
Neuroanatomic factors
Among the neurobiological mechanisms involved in the development of posttraumatic depression are injury to the left dorsolateral prefrontal cortex and left basal ganglia. 3, 33 Jorge et al 3 note an association between depression in the acute period following injury and significantly reduced left prefrontal gray matter volumes, especially in the ventrolateral and dorsolateral regions. It is suggested that volumetric changes in these areas may reflect a relative lack of activation of lateral and dorsal prefrontal cortices, and predispose to increased activation of ventral limbic and paralimbic structures, including the amygdala. This type of imbalance in the dorsal and ventral systems that permit normal regulation of emotion is consistent with recently proposed models of the neural mechanisms of depression. [34] [35] [36] [37] Jorge et al 12 also report a correlation between anxious depression and right hemisphere lesions, while major depression alone was more strongly associated with left anterior lesions. Lipsey et al, 38 in a report of 15 patients with bilateral brain injury secondary to thromboembolic stroke or trauma, showed a direct and significant relationship between injury proximity to the left frontal pole and the severity of depression. It has also been observed that prolactin response to buspirone, a serotonin 1A partial agonist, 39 was significantly blunted in post-head injury depressed patients compared with head injured nondepressed patients and normal controls, suggesting a role of serotonin dysfunction in depression after TBI. 40 In addition to serotonergic dysfunction, alterations in the availability or function of cerebral dopamine, norepinephrine, acetylcholine, and glutamate may be involved in the development of posttraumatic depression. 41 While the neural mechanisms by which depression results following TBI are not understood completely, these findings suggest that laterality of injury, proximity to and/or dysfunction in dorsal frontal systems, as well as dysregulation of serotonergic activity are most likely involved.
Psychosocial factors
The development and persistence of depression after TBI is also influenced by psychosocial factors. 29 The risk of posttraumatic depression may be increased by poor preinjury occupational status, 42 poor premorbid social functioning and/or poverty, 28 previous history of psychiatric diagnosis or brain injury, 33 alcohol abuse, fewer years of formal education, 30 female gender, 31 and a tendency to experience high levels of stress. 29 Changes in autonomy, self-image, and in close relationships are also common after TBI, and present substantial challenges to adaptation for the person with brain injury and his or her family. Unfortunately, many of these preinjury and postinjury personal and psychological factors are not modifiable after TBI, and those that may be amenable to psychosocial intervention are difficult to address at best (see the "Psychosocial Interventions" section). While undoubtedly contributory, the presence of these risk factors should not in all cases be equated with causality in posttraumatic depression. Instead, they should be viewed as influential factors whose consideration is required in the evaluation of persons with depression after TBI.
It has been reported that there are differences in the etiology of depressions that occur immediately after brain injury and those that occur later. Jorge et al 43 described a group of 66 patients admitted for the treatment of acute closed head injury. Acute-onset major depression (in those who met DSM-III criteria on initial examination at an average of 37 days after injury) was associated with specific brain lesion locations, particularly left dorsolateral frontal and/or left basal ganglia lesions. In contrast, delayed-onset (at 3, 6, or 12 months after injury) major depression was not related to lesion location, was less severe, and the patients had significantly poorer social function and less impairment in activities of daily living. This may suggest a greater role for biological factors in acute-onset major depressions after TBI, while psychosocial factors play a more significant role in delayedonset posttraumatic depressions. Finally, it is important to note that while somatization and malingering do occur, these are relatively uncommon conditions even in the context of medicolegal proceedings. 44 Without question, these should not be the first or the default diagnoses when patients present with difficult-to-diagnose symptoms, including depressive symptoms, following TBI. 45 Attribution of symptoms to malingering should be avoided unless (1) the patient demonstrates incontrovertible evidence of such on multiple neuropsychological measures designed for the specific identification of this problem and (2) there is clear demonstration of function in everyday life that is inconsistent with the patient's reported symptoms and that cannot be accounted for by other neuropsychiatric factors. In addition, it is important to consider the role of stresses attendant to medicolegal proceedings in the development and persistence of depressive symptoms after TBI. While the conclusion of such proceedings may afford a measure of relief from depressive symptoms in some persons with TBI, in many cases those symptoms will continue to require clinical attention and intervention thereafter.
PHARMACOLOGIC TREATMENTS
Depression after TBI is amenable to pharmacologic intervention, and may alleviate not www.headtraumarehab.com only the mood disturbance but also reduce other postconcussive symptoms and the patient's experience of the severity of such symptoms. 46 Although many factors may produce or contribute to apparent depressive symptoms, such as sleep disturbance, fatigue (anergia), difficulty concentration, anhedonia (apathy), and so forth, when there are sufficient symptoms to merit a diagnosis of depression-regardless of their other possible causes-antidepressant treatment should be initiated. When pharmacotherapy is initiated, it is recommended to start at low doses and to escalate dosing slowly (a "start low and go slow" approach), as persons with TBI are often treated with other medications that may increase the risk of adverse drug-drug interactions. In addition, and while acknowledging the limited evidence on this matter, common clinical experience suggests that persons with TBI may be more susceptible to medication adverse effects. These issues are considered in additional detail in the following sections, and summarized in Table 1 .
Selective serotonin reuptake inhibitors
The selective serotonin reuptake inhibitors (SSRIs) include sertraline, fluoxetine, paroxetine, citalopram, escitalopram, and fluvoxamine. These agents have, in recent years, become the mainstay of the treatment of idiopathic depression in light of their efficacy, relatively low burden of adverse effects, ease of dosing, and low risk of life-threatening overdose. Although the literature regarding the pharmacotherapy of depression following TBI is limited, these agents appear to afford similar benefits on depression after TBI, and therefore are recommended as the first-line agents for treatment of this condition. Other neuropsychiatric symptoms that often arise after TBI may also improve during treatment with the SSRIs, including irritability, aggression, anxiety, and poor impulse control.
Sertraline
Sertraline shows the best evidence for treatment effectiveness and tolerability among the SSRIs. In an 8-week, nonrandomized, singleblind, placebo run trial of 15 patients diagnosed with major depression between 3 and 24 months after mild TBI, the depression of 13 patients responded, and 10 remitted, by week 8 of sertraline treatment. 46 Response was defined as a 50% or greater reduction in HAM-D, while remission indicated an end-of-study HAM-D score of 7 or less. In addition, patients receiving sertraline showed significant reductions in psychological distress, anger, aggression, and postconcussive symptoms as well as improvements in global functioning. Sertraline doses ranged from 25 to 200 mg daily by the end of the study. This treatment was generally well tolerated, although 1 patient dropped out because of adverse effects. In a follow-up study with the same group of patients, Fann et al 47 reported treatment-related improvements in cognition, including improvements in psychomotor speed, recent verbal memory, recent visual memory, and general cognitive efficiency.
Further support for the use of sertraline for posttraumatic depression is offered by TurnerStokes et al. 26 These investigators conducted an open-label trial of sertraline for depression among 21 adults with brain injuries, including TBI. They report clinical improvement as assessed by DSM-IV criteria in all of these patients. They also report that 17 of these patients were able to complete the BDI before and after treatment, and that significant decreases in depressive symptoms were associated with treatment in this group. Of these, 11 had failed previous treatment with a different selective serotonin reuptake inhibitor.
Schmitt et al 48 investigated the cognitive effects of several SSRIs and their findings support, and perhaps inform, the observation of Fann et al 47 regarding improved cognition during treatment with sertraline. This study demonstrated significant improvements in verbal fluency among healthy middle-aged adults treated with sertraline 50 to 100 mg when compared to treatment with placebo, an effect attributed to sertraline's modest ability to inhibit dopamine reuptake. Such increases of dopamine would be expected to improve frontally mediated cognitive and behavioral function in this population. While this speculation is intriguing, no statistically significant treatment effect was found on these cognitive functions by Meythaler et al, 49 who performed a placebo-controlled trial of sertraline for arousal and attentional impairments in 11 subjects with severe TBI in the acute rehabilitation setting. Although the authors caution against overinterpretation of this finding in light of their small sample size, their results suggest that neither the serotonergic nor the dopaminergic reuptake inhibition properties of this agent are sufficient to produce marked improvements in cognition in persons with recent severe TBI. It is possible that among persons with TBI of milder severity, such as that experienced by subjects included in the report by Fann et al, 47 treatment with sertraline may confer cognitive benefits on the basis of resolving depression alone, augmenting other frontal functions, or both.
A more recent study 50 compared sertraline, methylphenidate, and placebo in the treatment of neuropsychiatric symptoms after TBI. They report improvements in depressive symptoms among subjects treated with either methylphenidate or sertraline, and noted that the magnitude of these improvements associated with either treatment were similar. However, subjects treated with methylphenidate experience greater improvements in cognitive performance and daytime wakefulness than subjects treated with sertraline. Although this finding does not challenge the finding of Fann et al 47 per se, it does suggest that persons with significant depressive and cognitive impairments following TBI may respond more effectively to treatment with methylphenidate than with sertraline.
Sertraline may also be of benefit for the treatment of irritability and aggression following TBI even when it is without specific benefit to related depressive symptoms. Kant et al 51 describe reductions in posttraumatic irritability and aggression (as assessed using the Overt Aggression Scale-Modified for outpatients) during treatment of 13 patients with sertraline at doses of 50 mg or greater. Although some changes in depressive symptoms (as assessed using the BDI) were also observed, these were not of a degree sufficient to produce statistical significance. It is possible that the relatively low doses of sertraline used in this study were inadequate for the treatment of depression, but were sufficient to treat irritability-predominant affective lability in a fashion consistent with other reports of the effects of low-dose SSRIs on such symptoms. 52 Collectively, these reports suggest that sertraline may be of benefit in the treatment of depression following TBI, and that such treatment may reduce other affective and postconcussive symptoms as well. As with all of the SSRIs, gastrointestinal adverse effects during treatment with sertraline are not uncommon, although these are in many patients dose-related and/or transient (ie, associated with treatment initiation or dose escalation). The relatively short half-life (approximately 26 hours) of this agent permits development of steady-state plasma levels within the first week of treatment in most patients and similarly permits relief from intolerable adverse effects within a relatively short period of time when treatment discontinuation becomes necessary.
Fluoxetine
Several reports suggest that fluoxetine may be of benefit in the treatment of depression following TBI. Cassidy 53 conducted an openlabel trial using fluoxetine for 8 patients with severe TBI and associated depression and observed marked improvement in 2 patients and moderate improvement in 3 patients. Half of these patients experienced sedative adverse effects, and 3 of the 8 patients reported an increase in anxiety. Bessette 47 with respect to improved cognition in association with reduced depressive symptoms, but they extend that finding to suggest a possible benefit of this agent on cognition more generally. Horsfield et al 56 further note fluoxetine's ability to stimulate the expression of brainderived neurotrophic factor (BDNF) and its specific tyrosine kinase receptor, which has in rodents been demonstrated to produce neuritic elongation and increased dendritic branching density of some hippocampal neurons, and suggest that similar mechanisms may be operative in humans. However, this suggestion is entirely speculative at present.
As with sertraline, the most common adverse effects of fluoxetine are sexual dysfunction and/or gastrointestinal, and these are often dose-related and/or transient. It is noteworthy that treatment-related anxiety and insomnia occur in approximately 20% of patients without brain injuries, 57 which may offer some explanation for the rate of treatmentemergent anxiety described by Cassidy. 53 In addition, seizure during treatment with fluoxetine in a brain-injured patient has been reported. 55 However, it is difficult to draw any conclusions regarding the safety (or efficacy) of this medication with respect to seizure or any other adverse effects on the basis of the available literature. The authors of this article remain circumspect with regard to the potential for fluoxetine to lower significantly the seizure threshold among persons with TBI, including those with posttraumatic epilepsy, on the basis of our experience using this medication in this population. Nonetheless, the published observation of precipitation of posttraumatic seizures with this and other antidepressant medications (see later) suggests that the possibility of altering seizure threshold by their administration should not be dismissed offhandedly. At a minimum, we suggest that this possibility be discussed prior to initiating treatment with these (or almost any) antidepressant agents.
Two case reports describe problematic drug-drug interactions with fluoxetine in persons with TBI. The first describes new-onset dysarthria and "speech blocking"when fluoxetine was added to trazodone in a man with a fall-related TBI. 58 Both of these treatmentemergent symptoms resolved following discontinuation of fluoxetine. The second report describes the development of hypomania in a woman with depression following TBI who added St John's wort and ginkgo biloba to her ongoing regimen of fluoxetine and buspirone. 59 Her hypomania remitted following discontinuation of these herbal agents. While this case report is instructive with respect to the development of this problem with this particular combination of medications, clinicians should be mindful of the risk of inducing hypomania (or mania) when using fluoxetine or other antidepressants more generally. While these cases are presented in the context of fluoxetine for depression following TBI, it is important to note that these and other drug-drug interactions are possible during treatment with any of the SSRIs. As such, the reporting of such cases may or may not reflect a propensity for problematic drug-drug interactions with fluoxetine as compared to the other agents in this class.
Despite these reports, we do not regard the rate of adverse effects during treatment with fluoxetine to be sufficiently problematic as to preclude treatment with this agent in this population. In clinical practice, patients often benefit from treatment with this agent, and do so without untoward effects in the majority of cases. However, it is important to note that the average half-life of the primary, and active, metabolite of fluoxetine (norfluoxetine) is on average at least 6 days. Given that elimination of this metabolite requires 4 to 5 half-lives to complete, patients who develop treatment-emergent adverse effects with fluoxetine may continue to experience such effects for several weeks following treatment discontinuation. Fluoxetine may also present additional challenges given its potential to interfere with the metabolism of other commonly prescribed medications. As such, while fluoxetine appears to be a reasonably effective treatment for depression following TBI, it may be somewhat less favorable for this purpose than sertraline.
Paroxetine
Paroxetine may be a useful treatment for depression in some patients, although there is at present only a single case report describing its use for the treatment of depression following TBI in a patient with "personality changelabile type due to traumatic brain injury." 60 The patient described might be understood as experiencing affective lability with some depressive features, and as such it is not clear that this study can be used to support the use of this medication for fully symptomatic depression following TBI. Nonetheless, paroxetine is in some cases used for this purpose and may be of value in this context.
As with the other SSRIs, the most common adverse effects produced by this agent are gastrointestinal. Sedation is also a common www.headtraumarehab.com adverse effect of paroxetine, occurring in almost 25% of general psychiatric patients receiving it. 57 It is commonly associated with weight gain, and its short half-life increases the risk of discontinuation syndrome. In addition, this agent possesses more significant antimuscarinic properties than the other SSRIs. 48, 61 These properties contribute to systemic anticholinergic adverse effects such as dry mouth and constipation, and also pose a risk for exacerbating cognitive impairments among persons with TBI. For example, Schmitt et al 48 demonstrated that healthy middle-aged adults experienced significantly greater impairments of delayed recall in a word-learning test during treatment with paroxetine 20 to 40 mg/d than during treatment with placebo, an effect attributed to paroxetine's nontrivial antimuscarinic properties. Given that TBI results in reduced cholinergic function in the majority of persons with TBI, 62, 63 one would predict that this might place persons with TBI at risk for similar or greater degrees of cognitive impairment during treatment with this agent. Although this remains speculation at present, clinicians should remain mindful of this possibility when undertaking treatment with paroxetine in this population. As with fluoxetine, both the available literature and the potential for adverse cognitive effects of this agent suggest that paroxetine should be considered second-line among the SSRIs for the treatment of depression following TBI.
Citalopram, escitalopram, and fluvoxamine
At the time of this writing, the only report describing treatment with citalopram does so in combination with carbamazepine for the treatment of mood and other neurobehavioral problems following TBI. 64 Subjects in this study were treated with 12 weeks of citalopram 20 mg/d and carbamazepine 600 mg/d in an open-label fashion. Clinical Global Impression (CGI) ratings and Brief Psychiatric Rating Scale (BPRS) scores were obtained before and after treatment with these agents, and were significantly improved by this combination therapy. These authors note that subjects with more remote TBI (24-36 months prior to study) improved to a lesser degree than did subjects with more recent TBI (within 6 months). It is not clear whether this observation reflects spontaneous recovery among the more recently injured subjects during the treatment period (ie, a false-positive treatment response) or instead suggests improved treatment responsiveness in the early period following TBI. In addition, the concurrent administration of both agents precludes attribution of the symptomatic improvements observed by the authors to one of these agents alone or their combination.
As with the other SSRIs, common clinical experience suggests that some patients with depression following TBI will benefit from treatment with citalopram. Its adverse effect profile, limited propensity for drug-drug interactions, and relatively short half-life make it attractive for use among persons with TBI. Although common clinical experience suggests this agent is useful in the treatment of posttraumatic depression, clinicians should be mindful of the absence of reports of its efficacy and tolerability in this population. Similarly, there are no reports regarding the use of either escitalopram or fluvoxamine for the treatment of depression following TBI. Our experience suggests that escitalopram is the more effective of these 2 for this purpose and is similar to citalopram with respect to efficacy, tolerability, and drug-drug interaction. However, these agents should be used with caution pending further study of their effects, and adverse effects, among persons with depression following TBI.
Tricyclic and tetracyclic antidepressants
This class of medications includes imipramine, amitriptyline, trimipramine, desipramine, nortriptyline, maprotiline, doxepin, and protriptyline. Since the advent of the SSRIs, tricyclic and tetracyclic antidepressants (TCAs) are used less commonly as first-line agents for the treatment of depression in general as well as depression following TBI. This pattern of prescription may in part reflect clinician's concerns regarding the possibility of increased adverse effects associated with these agents, reports of more limited effectiveness of these agents among persons with TBI, waning familiarity with the use of these agents on the part of recently trained clinicians, the risk of lethal overdose, or some combination of these factors. Regardless, there is less evidence to support the use of TCAs in the treatment of depression following TBI than there is for the SSRIs, and the limited evidence suggests that these agents may not be as effective in the treatment of depression following TBI as they are in the treatment of idiopathic major depressive episodes.
For example, Saran 65 conducted a crossover study of phenelzine and amitriptyline administered at therapeutic doses to 10 subjects with "minor brain injury"and 12 subjects with major depressive episodes without TBI. All of the subjects with "idiopathic" major depression improved after 4 weeks of amitriptyline but none of the subjects with depression following TBI improved. Of note, however, the depression experienced by these subjects was reported to be of the "melancholic" subtype, but significant weight loss and/or difficulty sleeping, which are typical symptoms of melancholic depression, were not present in these subjects. Accordingly, the diagnostic categorization of these subjects may not be fully accurate, and the interpretation of their findings is therefore difficult. Nonetheless, the lack of response to treatment with amitriptyline among persons with posttraumatic depression in this study is not encouraging with respect to the usefulness of this agent. Similarly, Dinan and Mobayed 66 reported that 85% of subjects with major depressive disorder responded to amitriptyline while only 31% of similarly depressed persons following TBI responded to this treatment. In contrast to these discouraging reports, Varney et al 1 report that 82% of 51 subjects with depression following TBI who received treatment with either TCAs or carbamazepine reported at least moderate relief of depressive symptoms. Collectively, these observations offer only modest support, at best, for the use of amitriptyline for depression following TBI. Accordingly, the authors do not recommend use of this agent in general and particularly in lieu of treatment with newer, less potentially problematic, and more consistently effective antidepressants.
Among the newer TCAs, nortriptyline and desipramine are used more commonly in clinical practice. However, there remains very limited evidence to guide their use and with which to assess the risks entailed by their use among persons with TBI. Wroblewski et al 67 performed a modified, blinded, placebo lead-in treatment study of 10 patients with depression following severe TBI using desipramine and observed improvement in 6 of the 7 (86%) patients able to complete the study. However, 3 (30%) patients discontinued the study, including 1 who developed seizures and 1 who developed mania during treatment. An additional patient experienced a seizure during treatment with desipramine but continued treatment with this medication nonetheless. While this study suggests that desipramine may be effective for the treatment of depression in some persons with TBI, it may also be associated with significant adverse effects such as seizure. While a single report offers little evidence with which to guide clinical practice, the findings from this study should be considered by clinicians and their patients prior to undertaking treatment with this agent.
When a TCA is prescribed for depression following TBI, nortriptyline is the one used most often. This may in part reflect its more favorable adverse effect profile in comparison to the other TCAs as well as its well-established effectiveness for depression following stroke. 68 However, stroke is not pathophysiologically equivalent to TBI, and the studies comparing antidepressant efficacy may not be equally applicable to both populations. Both stroke and TBI may produce discrete white matter lesions that interrupt catecholaminergic or serotonergic pathways (source, projection, or target), and mood disorders following such injuries may result from dysfunction in these neurotransmitter www.headtraumarehab.com systems. However, many persons with TBI may not suffer discrete lesions to these systems, but may instead experience diffuse axonal injuries; such injuries may modestly affect ascending catecholaminergic or serotonergic pathways and also glutamatergically dependent systems, cholinergic projections, and a host of other cortico-cortico or corticosubcortical pathways, cortical areas, and/or subcortical structures. In addition, TBI commonly involves bihemispheric injury, whereas such problems are rare following a single stroke. Therefore, the neuroanatomic and neurochemical consequences of TBI may not be the same as those resulting from stroke. Accordingly, there is reason to predict, and also to explain, observed differences in the response to treatment with TCAs between persons with depression following stroke and those with depression following TBI. Unfortunately, it is unlikely that more studies will be done to augment the limited data currently available investigating the efficacy and tolerability of the TCAs in persons with TBI.
As noted earlier, we suggest that the SSRIs be regarded as first-line treatment for depression following TBI. In the event that these agents fail to relieve posttraumatic depression and the use of a TCA is considered, we suggest use of either nortriptyline (initial dose of 25 mg/d) or desipramine (initial dose of 50 mg/d) following careful informed consent of the patient regarding the potential adverse effects and complications of these treatments. Treatment with these agents should proceed slowly, with dose increases no more often than every 3 to 7 days. Careful monitoring of plasma levels of the parent compound and its major metabolites should be undertaken, with a goal of driving levels into the therapeutic range while assessing the clinical effects of treatment at such dosages/levels (eg, nortriptyline levels 50-100 ng/mL; desipramine levels >125 ng/mL).
The most common and disabling adverse effects of TCAs among persons with neurological disorders are those associated with the anticholinergic properties of these medications, which can impair attention, concentration, and memory and cause dry mouth, diplopia, and constipation. For example, patients with Parkinson's disease have shown increased confusion when treated with anticholinergic medications. 69, 70 Experimental evidence in traumatically brain-injured rats supports this observation, 71, 72 as does common clinical experience in the treatment of patients with TBI. Such observations are consistent with the observed effects of both experimental and human TBI on cortical cholinergic function noted above. Amitriptyline, trimipramine, doxepin, and protriptyline have high affinities for muscarinic receptors; given their strong anticholinergic properties, these medications should be prescribed only after careful consideration (and preferably empiric trials) of less potentially problematic alternative medications.
If adverse effects such as sedation, confusion, urinary retention, sinus tachycardia or cardiac conduction disturbances, or symptomatic hypotension (orthostatic or otherwise) develop, dose reductions may alleviate these effects and also permit patients time to accommodate to these adverse effects. Of note, orthostatic hypotension occurs less often during treatment with nortriptyline than with the other TCAs. If the patient's adverse effects abate following dose reduction, gradual dose escalation may in some cases proceed without additional complication. If adverse effects limit dosing to subtherapeutic levels, augmentation or other treatment strategies may need to be considered.
Tricyclic antidepressants may also be associated with nontrivial rates of serious adverse events and, in particular, seizures. Wroblewski et al 73 reviewed the records of 68 persons with TBI who received antidepressant, and predominantly TCA, treatment for at least 3 months. The frequency of seizures was compared for the 3 months before treatment, during treatment, and after treatment. Seizures occurred among 6 subjects during the baseline period, 16 during antidepressant treatment, and 4 after treatment was discontinued. Fourteen subjects (20%) had seizures shortly after the initiation of treatment. For 12 of these, no seizures occurred after treatment when the antidepressant was discontinued. Importantly, 7 of these subjects were receiving anticonvulsant medication before and during antidepressant treatment. Of note, the occurrence of seizures was related to greater severity of brain injury. Although our experience suggests that the rate of seizures during treatment with TCAs in the late period following TBI is not as high as that observed by Wroblewski et al, 73 clinicians should be mindful of this potential adverse effect when prescribing TCAs to persons with TBI.
Novel antidepressants
The novel antidepressants include venlafaxine, mirtazapine, trazodone, and bupropion. Khouzam and Donnelly 74 report a reduction in TBI-induced compulsive behavior in response to treatment with venlafaxine. Teng et al 75 describe the use of bupropion for treatment-resistant restlessness in a patient with severe TBI during acute rehabilitation. However, at the time of this writing neither these nor any other reports describe the beneficial effects or treatment-emergent problems associated with the use of the abovementioned novel antidepressants among persons with posttraumatic depression. One report 76 describes the use of milnacipran, a serotonin-norepinephrine reuptake inhibitor available in Japan, in 10 persons with depression following mild or moderate TBI, and suggests that this agent is both an effective and safe treatment for depression. While this agent is not yet available in the United States, this report is encouraging for the potential benefits of mixed serotonin-norepinephrine reuptake inhibitors in this population.
Common clinical experience suggests that many of the novel antidepressants are useful in the treatment of depression following TBI, but their use must be undertaken with caution in light of the absence of data regarding their benefits and adverse consequences in this population. Of note, bupropion is often suggested to be associated with a higher incidence of seizures in otherwise healthy psychiatric patients. 77, 78 Such suggestions prompt caution prior to prescribing these agents in patients with depression following TBI. However, Johnston et al, 79 in a 102-site study of 1,986 patients treated with bupropion for depression, report seizure rates of 0.24% to 0.40%, and among those receiving 300 to 450 mg/d the cumulative rate of seizure was 0.36%. This large data set suggests that bupropion may not be more likely to reduce seizure threshold than other antidepressants. Whether the same will be true of bupropion's effects on seizure threshold among persons with TBI is not clear at present. While it may be overly cautious to suggest avoiding use of this agent for the treatment of depression following TBI, clinicians should consider the possibility that the dose at which increased risk of seizure emerges may be lower among persons with TBI than in the general population. Pending clarification of this issue, bupropion should be considered a second-line treatment for depression following TBI.
Monoamine oxidase inhibitors
Monoamine oxidase inhibitors (MAOIs) are not often used in persons with depression following TBI. This may reflect the high likelihood of difficulties with compliance to the complex dietary restrictions required during use of these medications given the cognitive impairments experienced by many TBI patients. In addition, the literature offers little support for the effectiveness of these medications in the TBI population. In the studies by Saran 65 
Other agents
Depressed mood due to TBI may respond to treatment with methylphenidate. Gualtieri and Evans 81 reported significant improvement on ratings of mood and cognitive performance among 15 patients with TBI following treatment with methylphenidate using a double blind, placebo-controlled crossover study design. These results were modest but suggestive of a possible role for methylphenidate in the treatment of both cognitive and mood disturbances following TBI. Although other studies offer support for the role of methylphenidate in the treatment of cognitive impairment following TBI, 82 it is not clear if or for how long such benefits on either mood or cognition might be sustained by this treatment. As noted earlier, Lee at al 50 demonstrated a beneficial effect of methylphenidate on cognition and depression among persons with TBI, and note that the magnitude of improvement on depressive symptoms was similar to that afforded by sertraline. Common clinical experience suggests that dextroamphetamine may be similar in its effects on mood and cognition following TBI, but no reports document a clear role for this medication in the treatment of depression following TBI. While these agents may be quite useful for the treatment of comorbid cognitive and depressive symptoms among persons with TBI, we suggest that these medications be regarded as potential adjunctive rather than primary agents for the treatment of depression following TBI pending additional studies of their use as primary treatments for posttraumatic depression alone.
Special pharmacotherapy considerations

Seizures and antidepressants
As noted above, some SSRIs, TCAs, and novel antidepressants may increase the risk for seizures during treatment of depression following TBI. This issue is raised frequently in clinical practice, but the magnitude of the risk posed by such treatments is unclear. Among patients with established epilepsy, Ojemann et al 83 found that seizure control does not appear to worsen if psychotropic medication is introduced cautiously and if the patient is on an effective anticonvulsant regimen. There are, at present, no indications that treatment of depression in patients with posttraumatic epilepsy differs from that in patients with epilepsy of other etiologies. While we conclude that antidepressants can be used safely and effectively in patients with TBI, including patients with posttraumatic epilepsy, we recommend that these agents be prescribed with caution and that treatment with them include assiduous monitoring for change in seizure frequency.
Drug-drug interactions
In addition to those already noted above, there are several important drug interactions that may occur during combined use of antidepressants and other medications prescribed commonly for persons with neuropsychiatric symptoms due to neurological conditions. 84 Many antiparkinsonian drugs and neuroleptics have anticholinergic effects that are additive to those of the antidepressants. Antidepressant levels are likely to be decreased-often below the therapeutic range-by the anticonvulsants phenytoin, carbamazepine, and phenobarbital. Similarly, antidepressants such as fluoxetine may raise the plasma levels of the anticonvulsants phenytoin, 85 valproic acid, 86 and carbamazepine. 87 Carbamazepine induces the metabolism of sertraline, and coadministration may therefore entail increased doses of the latter during treatment with the former. In light of these considerations, patients receiving treatment with medications that require therapeutic blood level monitoring should be afforded more frequent clinical assessments and serum monitoring when antidepressants are administered.
ELECTROCONVULSIVE THERAPY
Electroconvulsive therapy (ECT) remains a highly effective and underutilized modality for the treatment of depression in general, and it appears to be an effective treatment of depression following acute TBI. [88] [89] [90] Kant et al 91 reported on the safety and efficacy of ECT in subjects with head injury in a retrospective review of 11 subjects hospitalized as a result of neuropsychiatric problems after TBI. Among these subjects, 9 experienced a major depression or other mood disorder due to TBI. All of the subjects with neuropsychiatric problems due to TBI responded favorably to ECT as assessed by the Montgomery-Asberg Depression Rating Scale and Global Assessment of Functioning Scale, and did so without significant adverse cognitive or physical sequelae. Functional improvement occurred irrespective of baseline cognitive functioning or severity of injury. These studies suggest that ECT may be a safe treatment for chronic and severe neuropsychiatric disorders due to TBI. When ECT is used for the treatment of posttraumatic depression, we recommend use of the lowest possible energy levels that will generate a seizure of adequate duration (greater than 20 seconds), using pulsatile currents, increased spacing of treatments (2-5 days between treatments), and fewer treatments in an entire course (ie, [4] [5] [6] . If the patient also suffers from significant cognitive (especially memory) impairments due to TBI, nondominant unilateral ECT may be a preferable technique for subsequent treatment sessions.
PSYCHOSOCIAL INTERVENTIONS
Psychosocial factors undoubtedly contribute to the development and persistence of posttraumatic depression. While these factors may be difficult to address, consideration of their role in the development and persistence of depressive symptoms after TBI is imperative. In particular, family dynamics and coping with injury merit consideration. Both the literature and common clinical experience suggest that TBI produces significant stress and disability not only among persons with TBI but also among the family members and/or caregivers of those individuals. Rates of depression are significantly elevated in caregivers of patients after TBI, 92, 93 and posttraumatic neurobehavioral symptoms are associated with significant family dysfunction after TBI. 94 In addition, the ability of the family to effectively utilize problem-solving and behavioral coping strategies has been significantly correlated with lower levels of depression among persons with TBI. 95 While some of the psychosocial risk factors (gender, preinjury social and occupational function, years of formal education, etc) for posttraumatic depression are not modifiable, those that may be amenable to intervention (ie, family dynamics and coping strategies) should be addressed when possible.
For example, Hibbard et al 96 report that persons with TBI and their families may benefit from peer support programs in the postinjury period. In their study, participants reported that a peer support program increased their knowledge about TBI, enhanced their overall quality of life, improved general outlook, and enhanced their ability to cope with depression after TBI.
Similarly, sexual functioning and satisfaction within a couple affected by TBI contributes to both depression and quality of life in the aftermath of TBI. Persons with TBI and their significant others report negative changes in sexual behavior and sexual satisfaction after TBI. Although factors such as changes in physical function and body image are involved in a couple's sexual life after TBI, the most sensitive predictor of posttraumatic sexual dysfunction is depression. 97 Accordingly, recognizing and treating depression may improve not only this condition but also this very important part of a couple's life after TBI.
While studies of psychosocial interventions-including psychotherapy-are at present quite limited, the available literature and common clinical experience suggest that consideration of causative and/or complicating psychosocial factors is an essential element of the evaluation of persons with depression following TBI. It is possible that impairments in abstract thinking, insight, self-monitoring, and self-control may render some persons with TBI not well suited to undergo insight-oriented psychotherapeutic interventions. However, there is no consensus on this issue, and some authors argue that psychotherapies that focus on improving emotional states may be beneficial even among persons with severe posttraumatic cognitive impairments. 98 This remains an area that is both understudied and for which effective interventions are lacking, but is undoubtedly one that merits the attention of clinicians and researchers working with persons with TBI and their families.
CONCLUSIONS
It would be desirable if posttraumatic depression could be controlled by nonpharmacologic means alone. From a practical standpoint, assessment of psychosocial factors relevant to an individual's depression and use of psychosocial intervention targeting those factors seems both prudent and necessary. However, evidence regarding the use of nonpharmacologic treatments for posttraumatic depression is limited and in most cases the use of pharmacologic agents will be required to afford persons with TBI relief from their depressive symptoms.
In the treatment of idiopathic major depression, there is evidence that delay of effective treatment may result in refractoriness of the condition. 99 While it is not clear if this is true of posttraumatic depression, it is in our view reasonable to suggest that clinicians be vigilant for and quick to initiate pharmacological treatment of posttraumatic depression. The studies reviewed herein suggest that treatment of depression not only improves this condition, but may have considerable benefits on cognitive function, the number and perceived severity of postconcussive symptoms, functional outcomes, and psychosocial functioning among persons with TBI. Among the treatments presently available, the SSRIs are recommended as first-line treatments. Among these, sertraline is favored in light of its apparent effectiveness and tolerability. When this treatment fails to produce remission of posttraumatic depression, augmentation with a stimulant (ie, methylphenidate) or use of an antidepressant with a different mechanism of action may be required. Among persons with refractory posttraumatic depression or depressive symptoms that pose immediate risk to the patient's safety, ECT may be a lifesaving intervention. In all of these circumstances, consultation with a neuropsychiatrist familiar with the evaluation and treatment of depression following TBI may be of benefit to persons with TBI, their families, and clinicians providing care.
